---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-023680"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T11:54:19.983790+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Reviva Q2 net loss $12.4M; cash $11.2M; Phase 3 schizophrenia data due Oct 2023

## Summary
- Net loss of $12.4M ($0.55 per share) for Q2 2023 vs $5.3M ($0.29) a year ago.
- Cash $11.2M as of June 30, 2023, down from $18.5M at Dec 2022; runway into Q4 2023.
- Topline data for pivotal Phase 3 RECOVER trial of brilaroxazine in schizophrenia expected October 2023.
- Enrollment near completion (~400 patients); 1-year OLE study completion expected Q3 2024.
- May initiate Phase 2a studies in bipolar, MDD, ADHD in H2 2023 subject to additional financing.

## SEC filing metadata
- accession: 0001437749-23-023680
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774923023680/0001437749-23-023680-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774923023680/rvph20230809_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-023680
- JSON: https://secwatch.observer/filing/0001437749-23-023680.json
- Plain text: https://secwatch.observer/filing/0001437749-23-023680.txt

## Key facts
- Earnings Releases
  REVIVA PHARMACEUTICALS HOLDINGS, INC. reported six months ended June 30, 2023 results: net income net loss of approximately $19.0 million, EPS ($0.86) per share.
  - Period: six months ended June 30, 2023
  - Net income: net loss of approximately $19.0 million
  - EPS: ($0.86) per share
  - Result: reported results
  source text: The Company reported a net loss of approximately $19.0 million, or ($0.86) per share, for the six months ended June 30, 2023, compared to a net loss of approximately $12.7 million, or ($0.69) per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774923023680/0001437749-23-023680-index.htm
- Earnings Releases
  REVIVA PHARMACEUTICALS HOLDINGS, INC. reported second quarter ended June 30, 2023 results: net income net loss of approximately $12.4 million, EPS ($0.55) per share.
  - Period: second quarter ended June 30, 2023
  - Net income: net loss of approximately $12.4 million
  - EPS: ($0.55) per share
  - Result: reported results
  source text: The Company reported a net loss of approximately $12.4 million, or ($0.55) per share, for the three months ended June 30, 2023, compared to a net loss of approximately $5.3 million, or ($0.29) per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774923023680/0001437749-23-023680-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.